TIANJIN HUALIDA BIOLOGCAL ENGINEERING CO., LTD. is one of the first companies which realize industrialization of genetic engineering, as well one of the first important high-tech technology industrialized projects supported by Tianjin government. The leading product of the Company is "INTERFERON"¦Á-2b INF of genetic engineering which is the first choice for clinical treatment for chronic hepatitis and leucocythemia, which applies international level technology, and occupies a broad market all over China, and countries in Europe, Asia, and South America.
In 2002, the 10th meeting of Board of Directors of China Zhongxin Pharmaceutical Group Holding Co., Ltd and US XiKang Pharm Group, decided to increase investment in Hualida, so as that the registered capital reached 19.94 million USD, and also decided to establish Hualida Bio-Tech Park in TEDA, with total investment of 250 million RMB, and area of 76,000 sq. m, which held foundation ceremony in September 16, in TEDA.
Hualida Bio-Tech Park is schemed, designed and constructed by world-famous pharmaceutical engineering company, and is the first class bio-tech factory satisfying international standard of GMP and FDA. After establishment of Hualida Bio-Tech Park, the productivity of genetic engineering ¦Á-2b INF will be increased to 100 million, moreover, several INF series of products developed independently will be manufactured, as well some new medicines will be introduced from overseas.
Key Industries Brief